Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane L Grogan

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Nature Immunology|January 14, 2003
CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitmentHélène Bour-Jordan, Jane L Grogan, Qizhi Tang, et al.
Plos One|March 20, 2012
In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-diseaseEugene Y Chiang, Ganesh Kolumam, Krista M McCutcheon, et al.
Parasite Immunology|February 1, 2005
Human IgE response to the Schistosoma haematobium 22.6 kDa antigenC M Fitzsimmons, T J Stewart, Karl F Hoffmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2003
Basal chromatin modification at the IL-4 gene in helper T cellsJane L Grogan, Zhi-En Wang, Sarah Stanley, et al.
Advances in Immunology|May 12, 2004
Th2 cells: orchestrating barrier immunityDaniel B Stetson, David Voehringer, Jane L Grogan, et al.
Nature Immunology|November 26, 2008
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cellsTom Cupedo, Natasha K Crellin, Natalie Papazian, et al.
Frontiers in Immunology|June 8, 2026
Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understandingVictoria P Werth, Lars Rönnblom, Joerg Wenzel, et al.
Arthritis Research & Therapy|January 10, 2012
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trialBrinda Emu, Diana Luca, Carolyn Offutt, et al.
Arthritis Research & Therapy|November 1, 2014
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)William P Kennedy, J Abraham Simon, Carolyn Offutt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2012
Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clusteringKatharina F Stengel, Kristin Harden-Bowles, Xin Yu, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Nature Immunology|January 14, 2003
CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitmentHélène Bour-Jordan, Jane L Grogan, Qizhi Tang, et al.
Plos One|March 20, 2012
In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-diseaseEugene Y Chiang, Ganesh Kolumam, Krista M McCutcheon, et al.
Parasite Immunology|February 1, 2005
Human IgE response to the Schistosoma haematobium 22.6 kDa antigenC M Fitzsimmons, T J Stewart, Karl F Hoffmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 10, 2003
Basal chromatin modification at the IL-4 gene in helper T cellsJane L Grogan, Zhi-En Wang, Sarah Stanley, et al.
Advances in Immunology|May 12, 2004
Th2 cells: orchestrating barrier immunityDaniel B Stetson, David Voehringer, Jane L Grogan, et al.
Nature Immunology|November 26, 2008
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cellsTom Cupedo, Natasha K Crellin, Natalie Papazian, et al.
Frontiers in Immunology|June 8, 2026
Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understandingVictoria P Werth, Lars Rönnblom, Joerg Wenzel, et al.
Arthritis Research & Therapy|January 10, 2012
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trialBrinda Emu, Diana Luca, Carolyn Offutt, et al.
Arthritis Research & Therapy|November 1, 2014
Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)William P Kennedy, J Abraham Simon, Carolyn Offutt, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2012
Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clusteringKatharina F Stengel, Kristin Harden-Bowles, Xin Yu, et al.
Pageof 5